Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 19/20 | 0.54 |
| ▸ | MMP1 | P03956 | 14/20 | 0.54 |
| ▸ | MMP9 | P14780 | 13/20 | 0.54 |
| ▸ | MMP13 | P45452 | 11/20 | 0.54 |
| ▸ | MMP14 | P50281 | 4/20 | 0.49 |
| ▸ | ADAM10 | O14672 | 3/20 | 0.49 |
| ▸ | MMP7 | P09237 | 1/20 | 0.49 |
| ▸ | MMP8 | P22894 | 1/20 | 0.49 |
| ▸ | MMP2 | P08253 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6756491 | 0.94 | ADAM17 (0.52) | ADAM17MMP1MMP9MMP13MMP14 | |
| SCHEMBL7234022 | 0.83 | ADAM17 (0.59) | ADAM17MMP1MMP9MMP13MMP14 | |
| SCHEMBL6498496 | 0.82 | ADAM17 (0.54) | ADAM17MMP1MMP9MMP13MMP14 | |
| SCHEMBL6501873 | 0.82 | ADAM17 (0.54) | ADAM17MMP1MMP9MMP13MMP14 | |
| SCHEMBL6508421 | 0.81 | ADAM17 (0.55) | ADAM17MMP1MMP9MMP13MMP14 | |
| SCHEMBL3947995 | 0.80 | ADAM17 (0.66) | ADAM17MMP1MMP9MMP13MMP14 | |
| SCHEMBL6754091 | 0.80 | ADAM17 (0.57) | ADAM17MMP1MMP9MMP13MMP14 | |
| SCHEMBL6530353 | 0.79 | ADAM17 (0.63) | ADAM17MMP1MMP9MMP13MMP14 | |
| SCHEMBL6650497 | 0.77 | ADAM17 (0.64) | ADAM17MMP1MMP9MMP13MMP14 | |
| SCHEMBL6501190 | 0.77 | ADAM17 (0.64) | ADAM17MMP1MMP9MMP13MMP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030212049-A1 | Acetylenic alpha-amino acid-based sulfonamide hydroxamic acid tace inhibitors | WYETH (US) | 2003-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212049-A1 | Acetylenic alpha-amino acid-based sulfonamide hydroxamic acid tace inhibitors | TNF, SI, TASP1 | ADAM17 29/4885MMP1 130/4885MMP9 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.